Patients with lupus are not protected from COVID-19.
作者信息
Sawalha Amr H
机构信息
Departments of Pediatrics and Medicine and Lupus Center of Excellence, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
出版信息
Ann Rheum Dis. 2021 Feb;80(2):e21. doi: 10.1136/annrheumdis-2020-217656. Epub 2020 Apr 24.
Abstract
摘要
相似文献
1
Patients with lupus are not protected from COVID-19.狼疮患者无法免受新冠病毒的侵害。
Ann Rheum Dis. 2021 Feb;80(2):e21. doi: 10.1136/annrheumdis-2020-217656. Epub 2020 Apr 24.
2
Cyclosporine may reduce the risk of symptomatic COVID-19 in patients with systemic lupus erythematosus: a retrospective cohort study.环孢素可能降低红斑狼疮患者发生有症状 COVID-19 的风险：一项回顾性队列研究。
Microbiol Spectr. 2024 Nov 5;12(11):e0127624. doi: 10.1128/spectrum.01276-24. Epub 2024 Oct 15.
3
Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.COVID-19 患者伴系统性红斑狼疮，SARS-CoV-2 RNA 阳性复发后成功康复：病例报告及文献复习。
Clin Rheumatol. 2020 Sep;39(9):2803-2810. doi: 10.1007/s10067-020-05230-0. Epub 2020 Jul 28.
4
Are patients with systemic lupus erythematosus at increased risk for COVID-19?系统性红斑狼疮患者感染新型冠状病毒肺炎的风险会增加吗？
Ann Rheum Dis. 2021 Feb;80(2):e25. doi: 10.1136/annrheumdis-2020-217787. Epub 2020 May 25.
5
Response to: 'Are patients with systemic lupus erythematosus at increased risk for COVID-19?' by Favalli .
Ann Rheum Dis. 2021 Feb;80(2):e26. doi: 10.1136/annrheumdis-2020-217859. Epub 2020 May 25.
6
Response to: 'Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus' by Kondo .对近藤所著《系统性红斑狼疮患者中由COVID-19引发的免疫性血小板减少症恶化》的回应
Ann Rheum Dis. 2021 May;80(5):e78. doi: 10.1136/annrheumdis-2020-218176. Epub 2020 Aug 5.
7
Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.系统性红斑狼疮患者基线使用羟氯喹并不排除感染SARS-CoV-2及发生重症新型冠状病毒肺炎。
Ann Rheum Dis. 2020 Oct;79(10):1386-1388. doi: 10.1136/annrheumdis-2020-217690. Epub 2020 May 7.
8
No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit.目前尚无证据表明羟氯喹对预防新冠病毒病具有保护作用：乔布和维瓦尼特基的评论
Ann Rheum Dis. 2021 Feb;80(2):e22. doi: 10.1136/annrheumdis-2020-217665. Epub 2020 May 13.
9
Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics.2019年冠状病毒病大流行期间系统性红斑狼疮患者的羟氯喹短缺情况：系统性红斑狼疮国际协作诊所的经验
Ann Rheum Dis. 2021 Feb;80(2):1-2. doi: 10.1136/annrheumdis-2020-218164. Epub 2020 Jun 25.
10
COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients.COVID-19 在系统性红斑狼疮中的表现：一项针对 417 名患者的调查数据。
Semin Arthritis Rheum. 2020 Oct;50(5):1150-1157. doi: 10.1016/j.semarthrit.2020.06.012. Epub 2020 Jun 30.
引用本文的文献
1
SARS-CoV-2 and Systemic Lupus Erythematosus.新型冠状病毒与系统性红斑狼疮。
Curr Rheumatol Rep. 2021 Jan 28;23(2):8. doi: 10.1007/s11926-020-00973-w.
2
COVID-19 and autoimmune diseases.新型冠状病毒肺炎与自身免疫性疾病。
Curr Opin Rheumatol. 2021 Mar 1;33(2):155-162. doi: 10.1097/BOR.0000000000000776.
3
SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus.5例曾接受羟氯喹治疗系统性红斑狼疮的厄瓜多尔患者感染严重急性呼吸综合征冠状病毒2型及患新型冠状病毒肺炎情况
Am J Case Rep. 2020 Sep 26;21:e927304. doi: 10.12659/AJCR.927304.
4
[Not Available].[无可用内容]。
J Dtsch Dermatol Ges. 2020 Aug;18(8):815-825. doi: 10.1111/ddg.14195_g.
5
The correlation between SARS-CoV-2 infection and rheumatic disease.新型冠状病毒2019感染与风湿性疾病之间的相关性。
Autoimmun Rev. 2020 Jul;19(7):102557. doi: 10.1016/j.autrev.2020.102557. Epub 2020 May 1.
本文引用的文献
1
Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries.风湿性疾病与2019冠状病毒病：来自2019冠状病毒病全球风湿病联盟医疗服务提供者登记处的初步数据。
Lancet Rheumatol. 2020 May;2(5):e250-e253. doi: 10.1016/S2665-9913(20)30095-3. Epub 2020 Apr 16.
2
Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.羟氯喹在COVID-19危重症患者管理中的应用：循证依据的必要性。
Lancet Respir Med. 2020 Jun;8(6):539-541. doi: 10.1016/S2213-2600(20)30172-7. Epub 2020 Apr 15.
3
SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment.系统性红斑狼疮、羟氯喹与非系统性红斑狼疮的新冠肺炎患者：一则评论
Ann Rheum Dis. 2020 Jun;79(6):e61. doi: 10.1136/annrheumdis-2020-217506. Epub 2020 Apr 15.
4
Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients.表观遗传调控 ACE2 和干扰素调节基因可能提示狼疮患者 COVID-19 的易感性和严重程度增加。
Clin Immunol. 2020 Jun;215:108410. doi: 10.1016/j.clim.2020.108410. Epub 2020 Apr 8.
5
SARS-CoV-2 and HIV.严重急性呼吸综合征冠状病毒2型与人类免疫缺陷病毒
J Med Virol. 2020 Sep;92(9):1415. doi: 10.1002/jmv.25782. Epub 2020 Mar 27.
6
The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections.CD38/NAD/SIRTUIN1/EZH2 轴减轻细胞毒性 CD8+T 细胞功能，并鉴定出易患 SLE 感染的患者。
Cell Rep. 2020 Jan 7;30(1):112-123.e4. doi: 10.1016/j.celrep.2019.12.014.
7
Hydroxychloroquine in systemic lupus erythematosus (SLE).羟氯喹在系统性红斑狼疮（SLE）中的应用。
Expert Opin Drug Saf. 2017 Mar;16(3):411-419. doi: 10.1080/14740338.2017.1269168. Epub 2016 Dec 14.
8
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.美国关节炎及其他风湿性疾病患病率的估计。第一部分。
Arthritis Rheum. 2008 Jan;58(1):15-25. doi: 10.1002/art.23177.
Zotero 插件